<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01079364</url>
  </required_header>
  <id_info>
    <org_study_id>APIDR_L_04717</org_study_id>
    <secondary_id>2009-015742-34</secondary_id>
    <nct_id>NCT01079364</nct_id>
  </id_info>
  <brief_title>Better Acceptance of Single Injection Apidra Added to Once Daily Lantus Versus Twice Daily Premixed Insulin in Real Life Use Setting</brief_title>
  <acronym>BASAAL PLUS</acronym>
  <official_title>Better Acceptance of a Single Injection Apidra (Insulin Glulisine) Added to Once Daily Lantus (Insulin Glargine) Versus Twice Daily Premixed Insulin in a Real Life Use Setting</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sanofi</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Sanofi</source>
  <brief_summary>
    <textblock>
      Primary Objective:

      To demonstrate non-inferiority of once daily injection of insulin glargine (Lantus) plus one
      injection of mealtime insulin glulisine (Apidra) at the main meal versus twice daily premixed
      insulin (NovoMix 30/70) based on the reduction of HbA1c percentage from baseline to endpoint.

      Secondary Objective:

        -  To determine treatment satisfaction (DTSQs/Diabetes Treatment Questionnaire - Status,
           DTSQc/ Diabetes Treatment Questionnaire - change and ITSQ/Insulin Treatment Satisfaction
           Questionnaire)

        -  To determine the mean HbA1c, FBG (Fasting Blood Glucose), prandial BG (Blood Glucose)
           and proportion of patients with a HbA1c &lt;7%

        -  To determine the effect on adverse events (e.g. symptomatic hypoglycemic events, weight
           gain and injection site reactions)

        -  To determine the total insulin dose, average insulin glargine, insulin glulisine and
           premixed insulin dosages.
    </textblock>
  </brief_summary>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Slow recruitment
  </why_stopped>
  <start_date>January 2010</start_date>
  <completion_date type="Actual">July 2012</completion_date>
  <primary_completion_date type="Actual">July 2012</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Glycosylated Haemoglobin (HbA1c) Value</measure>
    <time_frame>at screening (week - 2), week 12 (if available) and 24</time_frame>
    <description>Glycosylated Haemoglobin (HbA1c) is a biological parameter that reflects the blood glucose concentration over a long period of time. It is the standard parameter for glycemic control follow -up in diabetic patients.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Self Measured Blood Glucose (SMBG)</measure>
    <time_frame>at Baseline (week 0), week 2, 12 and 24</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>DTSQs (Diabetes Treatment Satisfaction Questionnaire - status)</measure>
    <time_frame>at week 0, 12 and 24</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>DTSQc (Diabetes Treatment Satisfaction Questionnaire - change)</measure>
    <time_frame>at week 24</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>ITSQ (Insulin Treatment Satisfaction Questionnaire)</measure>
    <time_frame>at week 0, 12 and 24</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hypoglycemic events</measure>
    <time_frame>at week 0, 2, 12 and 24</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse Events (excluding hypoglycemic events)</measure>
    <time_frame>at week - 2, 0, 2, 12 and 24</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">52</enrollment>
  <condition>Diabetes Mellitus, Type 2</condition>
  <arm_group>
    <arm_group_label>Insulin glargine + Insulin glulisine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Daily injection of insulin glargine plus one injection of mealtime insulin glulisine at the main meal</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Premixed insulin</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>twice daily premixed insulin (before breakfast and evening meal).</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Insulin glulisine</intervention_name>
    <description>Pharmaceutical form: boxes of 5 SoloStar® pens Route of administration: injection Dose regimen: once a day</description>
    <arm_group_label>Insulin glargine + Insulin glulisine</arm_group_label>
    <other_name>Apidra®</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Insulin glargine</intervention_name>
    <description>Pharmaceutical form: boxes of 5 SoloStar® pens Route of administration: injection Dose regimen: once a day</description>
    <arm_group_label>Insulin glargine + Insulin glulisine</arm_group_label>
    <other_name>Lantus®</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Premixed insulin (Insulin Aspart 30/70 )</intervention_name>
    <description>Pharmaceutical form:boxes of 5 FlexPens Route of administration: Injection Dose regimen: twice daily</description>
    <arm_group_label>Premixed insulin</arm_group_label>
    <other_name>NovoMix 30/70®</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria:

          -  Patients with type 2 diabetes mellitus treated with insulin glargine once daily and
             oral blood glucose lowering medication

          -  Patients with a HbA1c &gt; 7%

          -  Patients with a FBG within range (4-7 mmol/L) at baseline, based on the mean of 3 FBG
             values (measured 5x during the run-in phase, with the highest and lowest value
             excluded)

        Exclusion criteria:

          -  Patients treated with an insulin other than insulin glargine

          -  Patients with hypersensitivity to insulin glargine, insulin glulisine, biphasic
             insulin aspart/insulin aspart protamine 30/70 or any of the excipients

          -  Patients with a (pre)proliferative retinopathy (an optic fundus examination should
             have been performed within the 2 years prior to study entry)

          -  Pregnant or lactating women

          -  Patients who are unable to fill in the PRO (Patient Reported Outcomes) questionnaires

        The above information is not intended to contain all considerations relevant to a patient's
        potential participation in a clinical trial.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Clinical Sciences &amp; Operations</last_name>
    <role>Study Director</role>
    <affiliation>Sanofi</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Sanofi-Aventis Administrative Office</name>
      <address>
        <city>Gouda</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Netherlands</country>
  </location_countries>
  <verification_date>May 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 25, 2010</study_first_submitted>
  <study_first_submitted_qc>March 2, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 3, 2010</study_first_posted>
  <last_update_submitted>May 27, 2013</last_update_submitted>
  <last_update_submitted_qc>May 27, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 29, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Insulin, Globin Zinc</mesh_term>
    <mesh_term>Insulin glulisine</mesh_term>
    <mesh_term>Insulin</mesh_term>
    <mesh_term>Insulin Glargine</mesh_term>
    <mesh_term>Insulin Aspart</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

